Skip to main content
PEN logo

Penumbra, Inc. (PEN) Stock: Price, Forecast & Analyst Target

Penumbra, Inc. (PEN) — MoonshotScore 92/100 (Exceptional band), calculated Nov 18, 2026. Price $320.00 (-0.19%), as of the Nov 19, 2026 trading session; market cap $12.6B. Expected results Feb 24, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 18.71× (cash as of Sep 30, 2026) · expected results Feb 24, 2027

$320.00 −$0.605 (-0.19%) Market Cap $12.6B

Penumbra, Inc. · PEN · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-13: Penumbra sells clot-removal, embolization and access devices for neurovascular and peripheral vascular procedures, with demand tied to clinician adoption and procedure use rather than broad healthcare spending. Revenue continues to expand, but recent earnings have not kept pace with sales. The case depends on whether Penumbra can convert further adoption of its thrombectomy platforms into stronger operating profit and cash generation without commercial spending absorbing the gains.

Price as of Nov 19, 2026

Key Statistics

92 of 100

MoonshotScore v2 · Penumbra (PEN)

Exceptional
Business Quality Elite (89)
Financial Safety Fortress (96)
Valuation Rich (36)
Growth Durability Compounding (89)
Momentum Rising (78)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.

  • quarterly revenue $355M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 19.12 · Piotroski F 5

Helping: business quality, balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PEN (57 recorded, newest six shown)
RecordedScoreBand
94Exceptional
94Exceptional
94Exceptional
94Exceptional
92Exceptional
92Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$320.00
Change on the day-0.19%
52-week range$276.01–$362.41
Market capitalisation$12.6B—
Price / earnings (trailing)79.98
Shares traded on the day195.8K
Beta (volatility vs the S&P 500)0.69

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $227, high $359, latest $320. 4 reported quarters marked, 1 above and 3 below the recorded estimate. $359 $227 high $359 Feb 25, 2026 · Earnings results · reported above the recorded estimate · close $3441May 6, 2026 · Earnings results · reported below the recorded estimate · close $3222Jul 30, 2026 · Earnings results · reported below the recorded estimate · close $3213Oct 29, 2026 · Earnings results · reported below the recorded estimate · close $3194 Oct 17, 2025 Nov 19, 2026 · $320 $249Oct 17, 2025$227Oct 31, 2025$280Nov 14, 2025$293Nov 28, 2025$312Dec 12, 2025$317Dec 26, 2025$322Jan 9, 2026$359Jan 23, 2026$341Feb 6, 2026$339Feb 20, 2026$339Mar 6, 2026$336Mar 20, 2026$330Apr 2, 2026$332Apr 17, 2026$325May 1, 2026$322May 15, 2026$318May 29, 2026$319Jun 12, 2026$317Jun 26, 2026$318Jul 10, 2026$319Jul 24, 2026$325Aug 7, 2026$325Aug 21, 2026$322Sep 4, 2026$318Sep 18, 2026$318Oct 2, 2026$321Oct 16, 2026$319Oct 30, 2026$321Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Penumbra (PEN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Strong
Valuation Weak
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Overvalued
Profit Margin Neutral
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Penumbra (PEN), and what does it report?

Short answer · as of

Penumbra designs, manufactures and markets systems used to remove thrombus, treat aneurysms and occlude peripheral vessels.

Its portfolio spans computer-assisted vacuum thrombectomy, aspiration systems, catheters, coils, delivery devices and neurosurgical tools, sold through direct sales organizations and distributors.

This is not a diversified medical-supplies business. The reported revenue reflects demand for focused neurovascular and peripheral vascular products such as the Penumbra System, Indigo System, Lightning Flash and Ruby Embolization Platform. Historical segment reporting places peripheral vascular alongside neuro as the principal reporting shape.

2 · Latest results

What do the latest results show for Penumbra (PEN)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $355M.

Revenue advanced from the preceding period and gross profit rose with it. Operating profit and net income also improved sequentially, yet both remained below their recent peak, while selling and administrative expense continued to climb.

The latest revenue result was close to expectations, but earnings fell short; the preceding report showed the same split between resilient sales and weaker earnings delivery. The statements point to expense conversion, not a collapse in product demand, as the immediate pressure: commercial spending has expanded faster than revenue over the comparable period, leaving operating profit only slightly higher.

The broader annual record remains constructive. Revenue has grown across the presented years, profitability recovered sharply in the latest completed year, and operating cash flow has stayed positive. Management commentary is not needed to establish the tension: sales momentum remains visible, while recent earnings and cash conversion have softened from stronger periods.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$410.14M Sep 30, 2026
Latest quarter · R&D
$25.36M Sep 30, 2026
Latest quarter · SG&A
$204.20M Sep 30, 2026
Latest quarter · FMP standardized operating result
$50.74M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$410.14M$25.36M$204.20M$50.74M
Jun 30, 2026$390.05M$25.40M$198.51M$41.04M
Mar 31, 2026$374.76M$22.38M$192.79M$38.23M
Dec 31, 2025$385.38M$21.79M$181.10M$59.23M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$410.14M Oct 29, 2026
Latest report · revenue estimate
$401.41M Oct 29, 2026
Latest report · revenue vs estimate
Above estimate Oct 29, 2026
Latest report · EPS vs estimate
Below estimate Oct 29, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 29, 2026$410.14M$401.41M$1.0700$1.2000
Jul 30, 2026$390.05M$389.64M$0.8800$1.1600
May 6, 2026$374.76M$370.47M$0.8200$1.0400
Feb 25, 2026$385.38M$361.87M$1.1800$1.1100
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$355M$46M$1.17 (diluted)
Q4 FY2025$385M$47M$1.20 (diluted)
Q1 FY2026$375M$33M$0.82 (diluted)
Q2 FY2026$390M$35M$0.88 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Penumbra (PEN)?

Short answer · as of

Cash and short-term investments were $673.61M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $41.51M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Penumbra carries substantial net cash, with cash and short-term investments comfortably exceeding total debt and total liabilities. Liquidity has also accumulated steadily across the reported history, while the distress screen does not signal balance-sheet strain.

Operating cash flow has remained positive after capital spending, giving the business internal funding capacity for product development and commercial expansion. The latest cash-flow result weakened from the preceding period, however, so continued balance growth should not be mistaken for uniformly improving conversion.

The sharper risk sits in the income statement. Selling and administrative costs have risen quickly while recent earnings have lagged revenue expectations, and the valuation embeds high sales and earnings multiples despite modest earnings and free-cash-flow yields. Slower adoption or continued expense growth could therefore pressure both profit conversion and the market’s growth assumptions.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 79.98 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$41.51M Sep 30, 2026
Previous quarter · operating cash flow
$46.08M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$41.51M−$15.11M
Jun 30, 2026$46.08M−$13.54M
Mar 31, 2026$86.97M−$13.67M
Dec 31, 2025$86.48M−$18.43M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Penumbra (PEN)?

Short answer · as of

The next earnings report is expected on Feb 24, 2027.

Penumbra’s next checkpoint is the relationship between product demand and expense conversion. Watch whether revenue keeps advancing, whether gross profit translates into faster operating-profit growth, and whether selling and administrative expense begins growing more slowly than sales.

Cash conversion deserves equal attention. A rebound in operating cash flow alongside continued cash accumulation would reinforce the quality of reported earnings; another decline while revenue rises would deepen the gap between commercial momentum and financial leverage.

Market estimates assume continued revenue and earnings expansion. The useful observation is not whether Penumbra clears a published estimate in isolation, but whether the recent pattern of near-plan sales and below-plan earnings begins to reverse.

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Nov 5, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Penumbra compare with its peers?

Short answer

Penumbra's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Penumbra is a focused thrombectomy and embolization company rather than a broad device conglomerate. Its portfolio connects neurovascular and peripheral vascular intervention through aspiration systems, catheters, coils and access products, making adoption of a relatively concentrated product family more consequential to overall performance.

That focus offers direct exposure to procedure use and product adoption, but it also concentrates execution risk in vascular intervention and the commercial organization supporting it. The market values Penumbra as a growth business, so comparison with similar device makers should emphasize sales-to-profit conversion and cash generation, not revenue growth alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Globus Medical, Inc. (GMED) Named competitor$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Same industry, near in market value$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Penumbra (PEN) — this page$320.00$12.6B92
LivaNova PLC (LIVN) Same industry, near in market value$94.54 Nov 18, 2026$5.21B88 5-pillar Nov 18, 2026
STERIS plc (STE) Same industry, near in market value$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$30.32 Nov 18, 2026$12.7B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Same industry, near in market value$103.32 Nov 18, 2026$19.6B79 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$370.17 Nov 18, 2026$9.95B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Named competitor$85.69 Nov 18, 2026$9.47B73 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$320.00 – $320.00
Consensus target
$320.00
Median target
$320.00

Consensus record · Captured .

Measured against a quoted price of $320.00 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 16, 2026

Transactions
9
Identified insiders
4
Purchases
0
Sales
0
Other transactions
9

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
88.9% Period end Sep 30, 2026
Previous quarter · ownership
87.8% Prior to period end Sep 30, 2026
Reporting holders
456 Period end Sep 30, 2026
Previous quarter · holders
477 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.4,300,206
Hbk Investments L P1,881,725
Vanguard Capital Management LLC1,704,378
Vanguard Portfolio Management LLC1,634,275
Ubs Group AG1,466,748

Tracked investors

Which of the 16 named investors we follow held PEN in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PEN in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Penumbra (PEN) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What does the Indigo System contribute to Penumbra’s business?

The Indigo System extends Penumbra’s clot-removal portfolio into peripheral vascular procedures through aspiration-based thrombectomy. It makes peripheral intervention a core source of demand alongside the company’s neurovascular products.

Why can Penumbra’s revenue rise while earnings disappoint?

Recent reports paired resilient revenue with earnings below expectations. Selling and administrative expense has grown quickly, so additional gross profit has not flowed through proportionately to operating and net income.

What does the Ruby Embolization Platform add beyond Penumbra’s thrombectomy products?

Ruby consists of detachable coils for peripheral embolization, supported by delivery and packing products. It gives Penumbra exposure to vessel occlusion procedures as well as clot removal.

Can Penumbra fund further development of Lightning Flash and the Indigo System?

Cash and short-term investments exceed debt by a wide margin, and operating cash flow remains positive after capital spending. That provides internal funding capacity, although the recent decline in operating cash flow makes conversion an important continuing check.

What is the PEN stock price today?

The last price recorded for Penumbra, Inc. (PEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PEN price target?

The analyst consensus price target for Penumbra, Inc. (PEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 1 from SEC filings and earnings calls, 73 from Financial Modeling Prep (FMP), 2 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters
  • 1. What is Penumbra (PEN), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Penumbra (PEN)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Most recent periodic reports
  • 3. What are the financial strengths and risks for Penumbra (PEN)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Distress and quality screens; Reported versus estimated, last 8 quarters
  • 4. What should you watch next at Penumbra (PEN)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
  • 5. How does Penumbra compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Analyst revenue and earnings estimates (average)
  • FAQ: What does the Indigo System contribute to Penumbra’s business?: Business description; Revenue by segment
  • FAQ: Why can Penumbra’s revenue rise while earnings disappoint?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: What does the Ruby Embolization Platform add beyond Penumbra’s thrombectomy products?: Business description
  • FAQ: Can Penumbra fund further development of Lightning Flash and the Indigo System?: Business description; Cash, investments and debt; Cash and investment components; Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.